Bedrijfsoverzicht
Arcellx, Inc. is a biotechnology entity dedicated to the development of various immunotherapies designed for patients suffering from cancer and other incurable diseases within the United States. The company operates within the healthcare sector, specifically focusing on the biotechnology industry, which implies a reliance on intensive research and development to bring novel therapies to market. In terms of scale, Arcellx, Inc. carries a market capitalization of $6.72B while reporting a trailing twelve-month revenue of $22.29M and employing a workforce of 209 individuals. The disparity between the substantial market capitalization of $6.72B and the relatively modest annual revenue of $22.29M indicates that the company's valuation is driven primarily by the potential future value of its pipeline assets rather than current earnings power or established cash flow generation.
Financiële gezondheid
The financial performance of Arcellx, Inc. over the trailing twelve months shows a revenue of $22.29M, which contrasts sharply with a net income of -$228,934,000 and an EBITDA of -$246,404,992. The significant gap between the positive revenue of $22.29M and the substantial net loss of -$228,934,000 reveals a cost structure where operating expenses, likely dominated by clinical trial costs and R&D investments, far exceed the income generated from sales. The company maintains a free cash flow of -$97,093,872, which indicates a consumption of cash reserves rather than cash generation, a common characteristic for biotechnology firms in the development phase but one that limits immediate financial flexibility. When analyzing profitability metrics, the gross margin stands at 0.0%, the operating margin is -3850.2%, and the profit margin is 0.0%, collectively indicating that the company has not yet achieved operational profitability and is burning cash to advance its lead product candidate. On the balance sheet, the company holds $450.33M in cash against total debt of $51.92M, supported by a debt-to-equity ratio of 12.90, suggesting a leveraged position where equity is significantly diluted relative to debt obligations despite the high cash balance. The current ratio of 4.43 demonstrates a strong position in short-term liquidity, as current assets are more than four times current liabilities, providing a substantial buffer against immediate financial obligations. Furthermore, the return on equity is -53.4% and the return on assets is -24.1%, metrics that reveal that management has not yet generated positive returns on the capital invested by shareholders or in the company's asset base due to ongoing heavy investment phases.
Waarderingsbeoordeling
The valuation of Arcellx, Inc. presents a complex picture with a trailing P/E ratio listed as N/A due to negative earnings, while the forward P/E is -66.29, implying that the market expects the company to remain unprofitable in the near term or that traditional earnings-based valuation models are not currently applicable. The price-to-book ratio is 16.53, which indicates a significant market premium over the company's book value, reflecting investor confidence in the potential of its immunotherapy pipeline to generate future value beyond its current net asset position. Alternative valuation metrics further highlight this premium, with a price-to-sales ratio of 301.32 and an EV/EBITDA of -25.64, suggesting that the market is pricing in substantial future growth potential despite current losses. Regarding price action, the 52-week high is $114.94 and the 52-week low is $47.86, placing the stock in a volatile range where the current valuation is heavily dependent on clinical trial outcomes rather than historical price stability. The beta value of 0.25 indicates that the stock exhibits low volatility relative to the broader market, moving less than half as much as the overall market index, which may offer a different risk profile for investors compared to typical high-beta biotechnology stocks.
Growth & Income
The revenue growth year-over-year is -89.2%, while earnings growth is N/A, indicating that the company is currently in a contractionary phase regarding revenue or that reported revenue has decreased significantly compared to the prior year period. Since the company does not pay a dividend, there is no dividend yield or payout ratio to analyze, meaning the company reinvests all available resources, including its $450.33M cash balance, directly into research and development activities rather than distributing income to shareholders. The overall growth and income profile of Arcellx, Inc. is characterized by a reliance on future clinical trial successes to drive revenue expansion, as evidenced by the negative revenue growth and the absence of any current dividend payments to support income-focused investment strategies.